Abstract Alzheimer's disease (AD), the most common cause of adult-onset dementia is
characterized by a progressive decline of cognitive functions accompanied by behavioral …

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Background: Earlier identification of cognitive impairment may reduce patient …

Background Alzheimer's disease is the commonest cause of dementia affecting older
people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of …

Background: The effectiveness of the 5 US Food and Drug Administration–approved
pharmacologic therapies for dementias in achieving clinically relevant improvements is …

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …

Alzheimer's disease (AD) is the most common form of degenerative dementia and is
characterized by progressive impairment in cognitive function during mid-to late-adult life …

Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …

Cholinergic neuron loss is a cardinal feature of Alzheimer disease. Nerve growth factor
(NGF) stimulates cholinergic function, improves memory and prevents cholinergic …

BACKGROUND: In the earliest clinical stages of Alzheimer's disease (AD) when symptoms
are mild, clinical diagnosis can be difficult. AD pathology most likely precedes symptoms …